Table 1.

Vaccine dosing details and clinical summary

Dog #	Baseline Disease Status	# of Tx	Vaccine Site	pDNA Dose (μg)	Day 57 Disease Status*	PFI (days from 1st Tx.)	Survival (days from 1st Tx.)†
1	Stage IV; Oral + lung mets‡	3	A	50	PD	0	101
			B	100
2	Stage IV; Oral/skin/lung mets§	1	A	200	PD	0	14
			B	400
3	Stage II; Oral¶	4	A	200	NED	412	412+
			B	400
4	Stage III; Oral**	4	A	50	PD	57	367
			B	100
5	Stage I; Dermal††	4	A	83 (ONCEPT®)‡‡	NED	433+	433+
			B	83 (in‐house)
6	Stage II; Dermal§§	4	A	700	NED	238+	238+
			B	GFP¶¶

Tx, treatment; PFI, progression‐free interval; mets, metastasis; PD, progressive disease; NED, no evidence of disease; GFP, green fluorescent protein. *Day 57 is the final scheduled study time point, 2 weeks after the fourth microseeding treatment. ^†Bolded and italicized values indicate dog was alive as of last update. ^‡3 cm oral mass resected with incomplete surgical margins. ^§3 cm mandibular lymph node, 2–14 mm skin and lung metastases. ^¶3.1 cm oral mass resected with incomplete surgical margins. **Oral primary melanoma measured 9.1 × 6.1 × 3.8 cm. Primary tumour irradiated weekly, for 4 weeks, final radiation Tx delivered concurrently with microseeding Tx. ^††5 mm dermal melanoma resected with narrow surgical margins. ^‡‡Commercial ONCEPT^® pDNA delivered by microseeding to Site A. ^§§3.3 cm dermal melanoma resected with complete surgical margins. ^¶¶Aldevron gWiz™ pDNA 100μg, 1 mg, 200 μg and 400 μg was delivered to Site B on the first, second, third, and fourth microseeding treatments, respectively.